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ORTHOTOPIC LIVER TRANSPLANTATION FOLLOWED BY DOUBLE CORD
BLOOD TRANSPLANTATION IN A PATIENTWITH ERYTHROPOIETIC PRO-
TOPORPHYRIA
Powell, J.L.1, Savo, A.M.3, Furuya, K.N.4, Consolini, D.M.2,
Malatack, J.2, Raab, C.P.2, Dunn, S.P.3, Kolb, E.A.1 1Alfred I. duPont
Hospital for Children, Wilmington, DE; 2Alfred I. duPont Hospital for
Children,Wilmington, DE; 3Alfred I. duPont Hospital for Children,Wil-
mington, DE; 4Alfred I. duPont Hospital for Children, Wilmington, DE
A 4 year old African American female presented with sun sensitiv-
ity related skin lesions and hepatomegaly with elevated liver enzymes
after a trip to the family beach home. Diagnostic work up revealed
elevated porphyrin levels consistent with erythropoietic protopor-
phyria with liver involvement. By 8 years of age, she had developed
end-stage liver failure with jaundice, coagulopathy, hypoalbumine-
mia and portal hypertension. Liver transplantation alone was not
a curative option for her, as her primary disorder would eventually
cause a transplanted organ to fail. Due to her failing hepatic function
we felt that she would not survive stem cell transplant alone. We de-
cided to pursue liver transplantation followed by stem cell transplan-
tation. Approximately 11 months after deceased donor liver
transplantation, a double cord blood allogeneic transplant was per-
formed. The patient was conditioned with busulfan (0.8 mg/kg/
dose q 6  16 doses on days -9 to -6), cyclophosphamide 50 mg/kg
q 24 hours  4 doses on days -5 to -2), and equine ATG (15 mg/
kg q 24 hours 3 doses on days -3 to -1). GVH prophylaxis was pro-
vided with cyclosporine and mycophenolate. The two cord blood
units had the following characteristics: both units were 4/6 matches.
The first unit was an allelic mismatch at B and DRB1, while the sec-
ond unit was a B antigen mismatch and DRB1 allelic mismatch. The
second unit was the ultimately engrafting unit. The patient was
CMV negative, the engrafting donor was CMV positive. Neutrophil
engraftment occured on day +26; platelet engraftment on day +170.
Transplant was complicated by several episodes of cholangitis and
bacteremia. The patient had grade II acute skinGVH after her trans-
plant, with grade III acute gut GVH, controlled with oral steroids,
oral budesonide, mycophenolate, etanercept, and cyclosporine. 89
days post cord blood transplant, zinc protoporphyrin levels have
fallen from pre transplantation levels of. 800mcg/dL to 139micro-
grams/dL. 197 days post cord blood cell transplantation, the patient
has normal hepatic synthetic function, total bilirubin of\0.1 mg/
dL, no evidence of hepatic graft rejection, subjective improvement
in overall skin coloration, cessation of porphyria related pain, and
no current active GVH. This represents to our knowledge the first
pediatric serial liver followed by double cord blood transplant for
erythropoietic protoporphyria.370
SEARCH PROCESS OF UNRELATED BLOOD AND MARROW TRANSPLAN-
TATION OF CATHOLIC BMT CENTER
Bok, J.-N., Kim, K.-S., Lee, S.-Y., Kim, J.-W., Choi, S.-E., Min, W.-S.
Seoul St. Mary’s Hospital, Seoul, Korea
The objective of the study was to evaluate patients in Catholic
BMT Center with unrelated blood and marrow transplant from do-
mestic and international donor registries from Jan. 2005 to Dec.
2007. At present, over 167,000 volunteer donors are registered in
Korea, and the probability of identifying HLA-A, B, DR serologi-
cally matched to unrelated donor was 62% in Korea, 80% in
NMDP, 62% in JMDP, 58% in CMDP, 47% in BTCSCC and
28% in ZKRD. According to the evaluation of distribution of do-
nors’ registries, it was listed in Korea 73.4%(n5 155), BTCSCC
10.9% (n5 23), NMDP 6.6% (n5 14), ZKRD 5.2% (n5 11),
and JMDP 3.8% (n5 8). As to the donors’ race, it came in the or-
der of: Korean 74.8% (n5 158), Asian-Pacific 17.1% (n5 36),
Caucasian 7.1% (n5 15) and non-specified 0.94% (n5 2). The
median period for coordination in each registry was 122.5 days in
NMDP, 123 days in ZKRD, 130 days in BTCSCC, and 140
days in Korea. Patients transplanted with 8 of 8 HLA allele
matched donor was 45.5% (n5 96), 7 of 8 allele match 35.1%(n5 74) and over 2 loci allele mismatch was 19.4% (n5 41). The
median period needed to identify the most compatible donor was
58 days. An optimum donor was identified after an average of 2.8
donors per patient were tested by HLA DNA sequencing molecu-
lar typing. Acute GVHD was higher in overseas donors (84.9%)
than that in Koreans (69.9%). 58.8% of patients among the popu-
lation showed to get chronic GVHD, 16.9% (N5 32) limited
grade of chronic GVHD and 42.8% (n5 81) extensive. There
was no significant difference in race (p5 0.25). Organs involved
with chronic GVHD were skin, oral mucosa, liver, eye in the order
of frequency. The number of days of the onset of chronic GVHD
was median post-transplant 169 days (range, 96-615). The period
of time identifying the most compatible donor shortened, and ac-
cordingly, the period from searching to transplant with a donor re-
duced as well. The probability of identifying a HLA serologically
matched to unrelated donor has been growing over 90% including
domestic and international registries as we can contact with avail-
able donors through NMDP and BMDW. However, the complica-
tion like GVHD still remains a problem to solve as they have
influence on outcome after blood and marrow transplanted. We
propose that we should keep on trying to find out an optimum do-
nor to minimize complications of patients with blood and marrow
transplanted, and the data should be collected continuously for
a follow-up survey and analysis.371
SUCCESSFUL CONCURRENT DOUBLE BONE MARROW TRANSPLANTA-
TIONS FOR TWO BETA-THALASSEMIA/HEMOGLOBIN E SIBLINGS FROM
ONE MATCHED UNRELATED DONOR
Vanichsetakul, P. Bangkok Hospital Medical Center, Bangkok, Thailand
Beta-thalassemia disease is a common inherited genetic disease in
Thailand. Bone marrow transplantation is worldwide acceptance to
potentially cure the disease. When the affected children have no
any HLA-matched siblings, they will require appropriate matched
unrelated healthy donors. Thalassemias and hemoglobinopathies
can affect in same immediate family members or siblings, in partic-
ular in the countries that these abnormal globin gene defects are
highly prevalent among their people. Same-parent siblings have
a chance to have HLA-matched to each other about 25%. The
event reported here is about concurrent double allogeneic bone
marrow transplantations performed simultaneously in two Thai
beta-thalassemia/hemoglobin E brothers, aged 3-year-10-month
and 1-year-8-month, using marrow stem cells from the same one
Taiwanese matched unrelated adult donor. These brothers were
fortunate to have similar HLA types and also compatible with
a matched unrelated donor identified by high resolution HLA typ-
ing method. The 29-year-old Taiwanese male donor was identified
and facilitated through the cooperation between National Blood
Centre, Thai Red Cross Society and Buddhist Tzu Chi Stem
Cell Donor Registry in Taiwan. His body weight was 90 kilogram
while the patients’ weights were 17 and 10 kilogram. The donor
and younger boy had same blood group O Rh positive but the elder
boy had group B positive. As bone marrow volume and stem cell
dose being estimated beforehands, the donor was harvested his
marrow in Taiwan for the sufficient amount for both patients in
the morning of transplant day. The marrow then was transported
by a courier flying back to Bangkok, and divided and infused to
each recipient at night on the same day. Mononuclear cell doses
per kilogram for elder and younger boys were 9.9 and 14.7 x108,
respectively, while CD 34 positive cell doses per kilogram were
10.1 and 13.5 x106, respectively. The patients were treated in two
separated HEPA-filtered rooms. Conditioning regimens used
were busulfex, cyclophosphamide, fludarabine, and ATG, while ta-
crolimus and methotrexate were utilized as GVHD prophylaxis.
Both of recipients had neutrophil recoveries evident on day +18.
They both achieved successful donor engraftment without
GVHD or any serious post-transplant complications. They under-
went the transplantations in August 2007 and have been regularly
followed up since. To date it is more than 2 years follow-up,
they are alive and very well, free of disease so far.
